+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Iron Deficiency Anemia Therapy Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 5176037
  • Report
  • August 2020
  • Region: Global
  • 118 Pages
  • Mordor Intelligence


  • Akebia Therapeutics Inc.
  • Allergen PLC
  • AMAG Pharmaceuticals Inc.
  • Pharmacosmos AS
  • Sanofi Aventis
The iron deficiency anemia therapy market is expected to register a CAGR of nearly 7.2%, during the forecast period, 2019-2024. Iron deficiency anemia is a common condition, especially affecting children and young women across the world. Iron deficiency anemia is a major problem in developed countries, such as the United States, Canada, the United Kingdom, and across Europe.

Moreover, in developing countries, iron deficiency anemia is frequently exacerbated by malaria and other worm infections. According to the World Health Organization, 2017, Africa bears the highest burden of malaria, with about around 90% cases. The current market is growing, due to the rising incidences of iron deficiency anemia. The increasing risk of hemodilution in pregnant women acts as a major driver for the market studied. The need to reduce the burden of iron-deficiency anemia has led to an increase in the demand for its treatment, which subsequently drives the global market.

Key Market Trends

Parenteral Iron Therapy Segment is Expected to Exhibit the Fastest Growth Rate over the Forecast Period

Parenteral iron therapy is generally offered to patients, who are either unable to absorb oral iron or are still diagnosed with increasing anemia, even after taking adequate doses of oral iron supplements. Many intravenous iron supplementation products are being approved by regulatory authorities, which is likely to drive the market in the future.
  • Furthermore, according to the study published in Cochrane Library, 2019, parenteral iron therapy has shown to be very effective, in the case of patients with inflammatory bowel disease, postpartum hemorrhage, and chronic heart failure. Additionally, advantages over oral therapy are expected to boost the demand for parenteral iron therapy. Some patients are intolerant toward oral iron therapy, hence, they prefer parenteral iron therapy. Therefore, the aforementioned factors are expected to influence positively on the market in this segment.

North America Captured the Largest Market Share and is Expected to Retain its Dominance

North America dominated the overall iron deficiency anemia therapy market, with the United States being the major contributor to the market. According to the study of Mechanisms of Ageing and Development, 2018, iron deficiency anemia is highly prevalent in pregnant women and children. In the United States, the prevalence rate of iron deficiency anemia was around 10% in women of childbearing age, while one-third of the children (12 months to 36 months) are likely to suffer from it.
  • Moreover, the increasing product approvals related to iron deficiency anemia therapy are expected to be major contributors to the market. For instance, recently, Pharmacosmos AS received a US FDA approval for its product, Monoferric, for the treatment of iron deficiency anemia. Hence, the high prevalence rate of anemia is expected to boost the growth of the market in North America.

Competitive Landscape

The companies are taking initiatives to develop novel therapies in the market studied. For instance, in 2018, AMAG Pharmaceuticals received a US FDA (Food and Drug Administration) approval for Feraheme, for the treatment of iron deficiency anemia in patients, with intolerance to oral iron therapy and/or have no significant improvement through oral iron therapy.
  • The presence of a significant number of players in the market studied has an impact on the prices of products by firms, such as Allergan PLC, Pharmacosmos AS, AMAG Pharmaceuticals Inc., Sanofi Aventis, Pieris Pharmaceuticals Inc., Keryx Biopharmaceuticals Inc., and Akebia Therapeutics.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Note: Product cover images may vary from those shown


  • Akebia Therapeutics Inc.
  • Allergen PLC
  • AMAG Pharmaceuticals Inc.
  • Pharmacosmos AS
  • Sanofi Aventis

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Prevalence of Anemia
4.2.2 Increasing Research and Development Activities Related to the Product
4.3 Market Restraints
4.3.1 Stringent Regulatory Guidelines
4.3.2 Adverse Effects
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5.1 By Therapy Type
5.1.1 Oral Iron Therapy
5.1.2 Parenteral Iron Therapy
5.1.3 Red Blood Cell Transfusion
5.1.4 Other Therapy Types
5.2 By End User
5.2.1 Hospitals
5.2.2 Clinics
5.2.3 Home Healthcare
5.3 By Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Allergen PLC
6.1.2 Akebia Therapeutics Inc.
6.1.3 AMAG Pharmaceuticals Inc.
6.1.4 Keryx Biopharmaceuticals Inc.
6.1.5 Luitpold Pharmaceuticals Inc.
6.1.6 Pharmacosmos AS
6.1.7 Pieris Pharmaceuticals Inc.
6.1.8 Sanofi Aventis
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Allergen PLC
  • Akebia Therapeutics Inc.
  • AMAG Pharmaceuticals Inc.
  • Keryx Biopharmaceuticals Inc.
  • Luitpold Pharmaceuticals Inc.
  • Pharmacosmos AS
  • Pieris Pharmaceuticals Inc.
  • Sanofi Aventis
Note: Product cover images may vary from those shown